Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
xconomy.com » Xconomy Boston - Oct 1, 2008
Life Sciences, ImmunoGen, Mitchel Sayer Ryan McBride wrote: ImmunoGen (NASDAQ:IMGN), a Waltham, MA-based biotech firm, announced today that its board of directors has approved a succession plan in which company …
Also tagged: boston, life sciences, boston briefs, daniel junius, mitchel sayer
xconomy.com » Xconomy - Sep 30, 2008
Life Sciences, ImmunoGen, Mitchel Sayer Ryan McBride wrote: ImmunoGen (NASDAQ:IMGN), a Waltham, MA-based biotech firm, announced today that its board of directors has approved a succession plan in which company …
Also tagged: boston, life sciences, boston briefs, daniel junius, mitchel sayer
xconomy.com » Xconomy Boston - Jul 1, 2008
Roundup, deals, Stocks Rebecca Zacks wrote: Aren’t things supposed to slow down in the summer? There was lots of dealmaking happening in New England last week, across life sciences and high-tech fields …
Also tagged: energy, microsoft, web 2 0, software, web, nanotech, roundup, vc, boston, venture capital, solar, deals, nano, stocks, acquisitions, bezos expeditions, checkpoint systems, life sciences, blogtalkradio, cleantech, cvs caremark, spark capital, industrial defender, gtc biotherapeutics, evergreen solar, healthvault, ovation pharmaceuticals, oatsystems, boston blog main, brook venture partners, rockport capital partners, teltone, rxi pharmaceuticals, ziff asset management, security innovation, arcapita ventures, reservoir capital group, lehman brothers venture partners, kraft group, aspen aerogels, biotech pharma
 |
$37 Million for Nanotech Insulation, $25 Million for ImmunoGen, $325 Million for Evergreen Solar, & More Deals Newsxconomy.com » Xconomy Energy Feed - Jun 30, 2008 Roundup, deals, Stocks Rebecca Zacks wrote: Aren’t things supposed to slow down in the summer? There was lots of dealmaking happening in New England last week, across life sciences and high-tech fields … Also tagged: energy, microsoft, web 2 0, software, web, nanotech, roundup, vc, boston, venture capital, solar, deals, nano, stocks, acquisitions, bezos expeditions, checkpoint systems, life sciences, blogtalkradio, cleantech, cvs caremark, spark capital, industrial defender, gtc biotherapeutics, evergreen solar, healthvault, ovation pharmaceuticals, oatsystems, boston blog main, brook venture partners, rockport capital partners, teltone, rxi pharmaceuticals, ziff asset management, security innovation, arcapita ventures, reservoir capital group, lehman brothers venture partners, kraft group, aspen aerogels, biotech pharma |
xconomy.com » Xconomy Boston - Jun 26, 2008
Roundup, Life Sciences, Alliances Rebecca Zacks wrote: New England’s public life sciences firms were feeling particularly newsworthy this last week, it seems. But plenty of private firms are represented in this first …
Also tagged: roundup, biotech, boston, deals, fda, stocks, pharma, carl icahn, alliances, life sciences, genzyme, biogen idec, gtc biotherapeutics, isis pharmaceuticals, ovation pharmaceuticals, boston blog main, kyowa hakko kogyo, innovationrx, alnylam pharmaceuticals, rxi pharmaceuticals, ziff asset management
 |
Health 2.0 Firms in the Spotlight, Biogen Board in the Clear, Alnylam in Asia, & More Life Sciences Newsxconomy.com » Xconomy Venture Capital Feed - Jun 25, 2008 Roundup, Life Sciences, Alliances Rebecca Zacks wrote: New England’s public life sciences firms were feeling particularly newsworthy this last week, it seems. But plenty of private firms are represented in this first … Also tagged: roundup, biotech, boston, deals, fda, stocks, pharma, carl icahn, alliances, life sciences, genzyme, biogen idec, gtc biotherapeutics, isis pharmaceuticals, ovation pharmaceuticals, boston blog main, kyowa hakko kogyo, innovationrx, alnylam pharmaceuticals, rxi pharmaceuticals, ziff asset management |
xconomy.com » Xconomy - Jun 24, 2008
Biotech, deals, Drugs Erik Mellgren wrote: Biopharma company ImmunoGen, (NASDAQ: IMGN), of Waltham, MA, announced today that it has sold 7.8 million shares at $3.20 per share to Ziff Asset Management. ImmunoGen, which …
Also tagged: drugs, biotech, boston, deals, boston briefs